Leigh Vosseller Sells 10,000 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) CFO Leigh Vosseller sold 10,000 shares of the stock in a transaction on Monday, September 13th. The stock was sold at an average price of $120.75, for a total value of $1,207,500.00. Following the transaction, the chief financial officer now owns 16,145 shares in the company, valued at approximately $1,949,508.75. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of TNDM stock opened at $123.10 on Friday. The business’s 50-day moving average price is $108.54 and its 200-day moving average price is $95.97. Tandem Diabetes Care, Inc. has a 12 month low of $76.19 and a 12 month high of $130.73. The firm has a market capitalization of $7.76 billion, a price-to-earnings ratio of 2,462.49 and a beta of 0.28. The company has a current ratio of 6.42, a quick ratio of 5.81 and a debt-to-equity ratio of 0.81.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, August 4th. The medical device company reported $0.06 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.14. Tandem Diabetes Care had a return on equity of 3.68% and a net margin of 1.08%. The firm had revenue of $172.14 million for the quarter, compared to analyst estimates of $143.36 million. During the same period last year, the firm posted ($0.45) earnings per share. The business’s revenue for the quarter was up 57.6% on a year-over-year basis. On average, sell-side analysts predict that Tandem Diabetes Care, Inc. will post 0.29 earnings per share for the current fiscal year.

TNDM has been the topic of several recent research reports. SVB Leerink increased their price objective on Tandem Diabetes Care from $102.00 to $123.00 and gave the stock a “market perform” rating in a research report on Thursday, August 5th. TheStreet upgraded Tandem Diabetes Care from a “d+” rating to a “c” rating in a research report on Wednesday, August 18th. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research report on Monday. Wells Fargo & Company raised their price target on Tandem Diabetes Care from $112.00 to $121.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 5th. Finally, Raymond James raised their price target on Tandem Diabetes Care from $115.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday, August 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of “Buy” and an average price target of $128.67.

Institutional investors have recently bought and sold shares of the stock. IFP Advisors Inc bought a new stake in Tandem Diabetes Care in the first quarter worth approximately $50,000. O Shaughnessy Asset Management LLC increased its holdings in Tandem Diabetes Care by 1,220.5% in the second quarter. O Shaughnessy Asset Management LLC now owns 515 shares of the medical device company’s stock worth $50,000 after purchasing an additional 476 shares in the last quarter. FinTrust Capital Advisors LLC increased its holdings in Tandem Diabetes Care by 40.0% in the second quarter. FinTrust Capital Advisors LLC now owns 735 shares of the medical device company’s stock worth $72,000 after purchasing an additional 210 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Tandem Diabetes Care in the first quarter worth approximately $77,000. Finally, GPS Wealth Strategies Group LLC increased its holdings in Tandem Diabetes Care by 68.8% in the second quarter. GPS Wealth Strategies Group LLC now owns 1,107 shares of the medical device company’s stock worth $108,000 after purchasing an additional 451 shares in the last quarter. 93.19% of the stock is currently owned by institutional investors.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Recommended Story: Stock Selection – What is cash flow?

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.